All In Biotech

Drug Trial Radar · NCT02369081

Optimum Treatment for Drug-Resistant Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

348

Actual

Start

May 2009

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
University of CambridgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
British Heart Foundation
First posted
Feb 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was recommended by NICE, as part of its 2006 guidance for the treatment of hypertension, and is urgently required to provide evidence for the treatment recommendations in patients with resistant hypertension. The study will be a randomised placebo-controlled double-blind crossover comparison of an α-blocker (α), β-blocker (β), and K+-sparing diuretic (∆). Patients will have a BP at entry above target on ABPM or home monitoring despite supervised administration of maximum tolerated doses of A+C+D. Over 48 weeks they will then receive, in random order either placebo or two doses each of doxazosin (α), bisoprolol (β) or spironolactone (∆). Each treatment cycle will last 12 weeks, with a forced dose-doubling at 6 weeks. The time course for the study will be similar to study one. 340 patients will provide 90% power, at α=0.01 to detect a 3 mmHg overall difference in home sBP between any one drug and placebo, with spironolactone hypothesized to be best overall. The study will be able to detect a 6 mmHg difference in sBP between each subject's best and second-best drug predicted by tertile of plasma renin, justifying routine use of the measurement in patients with resistant hypertension.

Conditions

  • Hypertension, Resistant to Conventional Therapy

Interventions

  • SpironolactoneDrug

    Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.

  • BisoprololDrug

    Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.

  • DoxazosinDrug

    Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.

  • PlaceboDrug

    Placebo treatment for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment arm comparison according to home blood pressure measurementTime frame: 48 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • NHS Ayrshire

    Ayrshire, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • University of Birmingham

    Birmingham, United Kingdom

  • University of Cambridge - Addenbrookes Hospital

    Cambridge, United Kingdom

  • NHS Tayside/University of Dundee

    Dundee, United Kingdom

  • NHS Lothian/University of Edinburgh

    Edinburgh, United Kingdom

  • Royal Devon & Exeter NHS Foundation Trust

    Exeter, United Kingdom

  • NHS Greater Glasgow and Clyde/University of Glasgow

    Glasgow, United Kingdom

  • Ixworth GP Practice

    Ixworth, United Kingdom

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom

  • Barts and the London School of Medicine and Dentistry

    London, United Kingdom

  • Guys and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Central Manchester University Hospitals NHS Foundation Trust

    Manchester, United Kingdom

  • Norfolk and Norwich University Hospital NHS Trust

    Norwich, United Kingdom

  • West Hertfordshire Hospitals NHS Trust

    Watford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.